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Efficacy and safety of a modular multi-modal
exercise program in prostate cancer patients with
bone metastases: a randomized controlled trial
Daniel A Galvão1*, Dennis R Taaffe2, Prue Cormie1, Nigel Spry3,4, Suzanne K Chambers5,6, Carolyn Peddle-McIntyre1,
Michael Baker1, James Denham7,8, David Joseph3,4, Geoff Groom9 and Robert U Newton1
Abstract
Background: The presence of bone metastases has excluded participation of prostate cancer patients in exercise
intervention studies to date and is also a relative contraindication to supervised exercise in the community setting
because of concerns of fragility fracture. However, this group of patients often have developed significant muscle
atrophy and functional impairments from prior and continuing androgen deprivation that is exacerbated by
subsequent and more intensive interventions such as chemotherapy. The aim of this study is to determine the
efficacy and safety of a modular multi-modal exercise program in prostate cancer patients with bone metastases.
Methods/Design: Multi-site randomized controlled trial in Western Australia and New South Wales to examine the
efficacy and safety of a modular multi-modal physical exercise program in 90 prostate cancer survivors with bone
metastases. Participants will be randomized to (1) modular multi-modal exercise intervention group or (2) usual
medical care group. The modular multi-modal exercise group will receive a 3-month supervised exercise program
based on bone lesion location/extent. Measurements for primary and secondary endpoints will take place at
baseline, 3 months (end of the intervention) and 6 months follow-up.
Discussion: Delaying or preventing skeletal complication and improving physical function for men with bone
metastases would provide clinically meaningful benefits to patients. However, exercise programs must be designed
and executed with careful consideration of the skeletal complications associated with bone metastatic disease and
cumulative toxicities from androgen deprivation such as osteoporosis and increased risk of fractures. The results
from this study will form the basis for the development of a specific exercise prescription in this patient group in
order to alleviate disease burden, counteract the adverse treatment related side-effects and enhance quality of life.
Trial Registration: ACTRN: ACTRN12611001158954
Background
Metastases to bone occurs in approximately 80% of men
with advanced prostate cancer [1] and the majority of
these patients are at risk of developing pathological frac-
tures, hypercalcemia, bone marrow suppression and
nerve compressions or spinal cord compressions that
result in significant morbidity, limited function and
decreased quality of life [2-4]. The clinical course of
metastatic bone disease in prostate cancer survivors is
relatively long, with a 5-year survival rate of approxi-
mately 30% [5]. Prostate cancer causes predominately
sclerotic lesions and commonly metastasize to the pelvis
and axial skeleton [6]. Therefore, patients with bone
metastases experience considerable morbidity resulting
from skeletal complications and fatigue secondary to
chemotherapy for those with castrate-resistance prostate
cancer [3,7]. Delaying or preventing skeletal complica-
tion, improving physical function and increasing levels
of physical activity in prostate cancer patients with bone
metastases can provide clinically meaningful benefits to
patients.* Correspondence: d.galvao@ecu.edu.au1Edith Cowan University Health and Wellness Institute and School of Exercise
and Health Sciences, Edith Cowan University, Joondalup, Australia
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Long-term androgen deprivation therapy (ADT)
remains the first-line treatment for advanced metastatic
prostate cancer, however it acts by inducing severe
hypogonadism causing a number of cumulative adverse
effects [8,9]. Some of these physical side effects include
reduction of bone and muscle mass, increased fat mass
and loss of neuromuscular strength [8,10]. We have
shown that a 9-month exposure to ADT led to signifi-
cant reductions in hip (1.5%), spine (3.9%), whole body
(2.4%) and upper limb (1.3%) bone mineral density
(BMD) [11]. We have also reported that men on ADT
had significantly reduced upper- and lower-body muscle
strength and impaired overall functional performance
and balance compared to healthy aged-matched controls
[12]. Notably, ADT has been associated with increased
fracture risks and more importantly this risk increases
with the number of doses of gonadotropin-releasing
hormone agonist administrated [8]. These observations
raise a major concern for men receiving long-term ADT
for advanced prostate cancer, with reduced muscle
strength placing prostate cancer patients at higher risk
of falling particularly when combined with ADT induced
reductions in bone strength, all of the sequelae of falls
and fracture. This is a major concern as fractures cause
significant morbidity and mortality in men [13] and has
been correlated with decreased survival in prostate can-
cer patients with bone metastases [14].
Apart from previous ADT, men with bone metastases
and castrate-resistant prostate cancer would commonly
receive chemotherapy given the results of initial phase
III trials indicating modest survival benefit for those
with symptomatic disease [15,16]. A number of well-
established adverse effects including nausea and severe
fatigue are associated with chemotherapy [15]. There-
fore, prostate cancer survivors with bone metastases suf-
fer not only from the treatment-related side effects
common to survivors with localised disease, but also
from significant physical [17] and psychological [18,19]
issues associated with bone metastatic disease and its
treatment.
Clinical trials investigating the efficacy of exercise in
prostate cancer survivors including our recent rando-
mized controlled trial excluded those who had bone
metastases [20-24], or bone lesions deemed
‘unstable’[25] due to the potential increased risk of ske-
letal fractures. Nevertheless, recent guidelines on Exer-
cise for Cancer Survivors by the American College of
Sports Medicine [26] suggest that cancer survivors
including those with bone metastases should “avoid
inactivity” given the potential benefits of physical activity
even for this group of cancer patients with advanced
disease. However, it remains to be determined if exercise
can be tolerated by patients with bone metastases given
the absence of clinical data on exercise feasibility and
efficacy in patients with bone metastases. This situation
is highly detrimental since patients with bone metastases
are reducing their physical activity levels for fear of bone
fracture and clinicians are reluctant to refer patients
with bone metastases for physical exercise programs.
Such a strategy can only result in greater fatigue,
reduced function and further declining muscle and ske-
letal integrity, greater risk of other chronic disease and
reduced quality of life [3,4]. This project is unique as it
tests the implementation of a modular multi-modal
exercise program (M3EP) taking into consideration loca-
tion/extent of bone metastases lesions as a strategy to
maintain or enhance physical function in this group of
patients with advanced prostate cancer. Further, the out-
comes from this trial may provide novel data that could
be translated to other cancer patients with bone metas-
tases. This is the first trial to our knowledge which is
specifically designed to address the potential beneficial
effects of exercise in cancer patients with bone
metastases.
Methods/Design
This is a two-armed prospective randomized controlled
trial that will examine the efficacy and safety of a modu-
lar multi-modal physical exercise program in prostate
cancer survivors with bone metastases. The trial will be
a multisite study with clinical sites in Western Australia
and New South Wales. Participants randomly assigned
to the M3EP exercise intervention group will receive a
3-month supervised exercise intervention program
(based on bone lesion location/extent) (Table 1). Partici-
pants in the usual medical care group will be asked not
to change their baseline levels of physical activity and
will be offered the same exercise program after the 3-
month control period if the intervention is deemed to
be feasible and efficacious.
Recruitment
Subjects will be recruited by invitation of their specialist
(radiation oncologist/urologists). Those entering the
study will undertake a series of familiarisation sessions
and baseline measurements prior to randomisation.
Table 1 Summary of study design
Months 0 3 6
Exercise (M3EP) Intervention (n = 45) Follow-up from 3-6 month
Usual Medical Care Usual Care (n = 45) Usual Medical Care to receive same intervention (M3EP) from 3-6 month
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Randomisation
Patients will be randomly allocated in a ratio of 1:1 to
the two study arms for the experimental M3EP exercise
intervention or usual medical care groups, subject to
maintaining approximate balance regarding stratification
for current chemotherapy (yes/no). A research methods
consultant with no patient contact will be responsible
for randomisation. The exercise physiologists and other
researchers conducting the study measures will be
blinded to a given participant’s group allocation. The
exercise intervention will be provided by exercise phy-
siologists not in the research team or performing the
tests.
Subjects
Ninety men (45 subjects per arm) with prostate cancer
and established bone metastases with no regular exercise
(undertaking structured aerobic or resistance training
two or more times per week) within the past 3 months
will be recruited through invitation by their attending
specialist in Perth, Western Australia, and the Central
Coast region of New South Wales. All participants will
require physician consent. Exclusion criteria will include
acute illness, significant bone pain, musculoskeletal or
cardiovascular or neurological disorders that could inhi-
bit or put them at risk from exercising. The protocol
has been approved (ID: 7699 GALVÃO) by the Edith
Cowan University Human Research Ethics Committee
and all participants will provide written informed
consent.
Calculation of sample size
Data from our research team in prostate cancer patients
indicates that the standard deviation (SD) for change in
our primary outcome which is the physical function
subscale of the Medical Outcomes Study Short-Form 36
(SF-36) equates to ~12 points following a 3-month
intervention. Given the health status of men in the pro-
posed study we anticipate that our 3-month exercise
regimen will result in an increase of ~5 points in the
physical function subscale of the SF-36 whereas the
usual medical care group will result in an overall loss of
~3 points over 3 months. Therefore, we anticipate a dif-
ference between the exercise and usual medical care
groups of ~8 points in change of the physical function
subscale from baseline to 3 months. A priori, 36 sub-
jects per group will be required to achieve 80% power at
an alpha level of 0.05 (two-tailed), and to demonstrate a
difference between groups at the end of the 3-month
intervention. Therefore, to adequately ensure that we
have sufficient subject numbers at the end of the inter-
vention (accounting for a drop-out rate of ~20%), 90
subjects will be randomized in a ratio of 1:1 to exercise
and usual medical care groups, respectively.
Measurements
Measurements for primary and secondary endpoints will
take place at baseline, 3 months (end of the interven-
tion) and 6 months follow-up.
Primary study endpoints
Physical function The physical function subscale of the
Medical Outcomes Study Short-Form 36 (SF-36) ques-
tionnaire will be used as an indicator of patient rated
physical functioning.
Secondary study endpoints
Objective measures of physical function A battery of
tests will be used to assess functional performance
[22,23,27]. Tests will be performed in triplicate (except
for the 400-m walk which will be performed once) with
sufficient recovery time between trials. The best perfor-
mance on each test will be used in the analyses. The
tests will be: 1) timed up and go, 2) 6-meter walk, usual
and fast pace, and 3) 400-m walk. Participants with
proximal femur bone lesion will be excluded from the
400-m walk test. Performance in each test will be timed
electronically using a Kinematic Measurement System
(Fitness Technology, SA, Australia).
Muscle strength Dynamic muscular strength of the
upper and lower body will be assessed using the one
repetition maximum (1RM) method [28]. The 1RM is
the maximal weight an individual can move through a
full range of motion without change in body position
other than that dictated by the specific exercise motion.
Participants will perform 1RM tests for the knee exten-
sion and chest press exercises using a standard 1RM
protocol [23]. Participants with proximal femur bone
lesion will be excluded from leg extension 1-RM. Parti-
cipants with axial skeleton (thoracic/ribs) bone lesion
will be excluded from chest press 1-RM. These exercises
were selected as they do not involve compression of the
spine or excessive load in the pelvic area.
Balance and risk of falling A Neurocom Smart Bal-
ancemaster (Neurocom, OR, USA) will be used to assess
static and dynamic balance. This device measures
ground reaction force to track whole body centre of
pressure and a tilting visual field and support platform
to separate the visual, somatosensory and vestibular bal-
ance sense of the patient [23]. Falls self-efficacy will be
determined using the Activities-Specific Balance Confi-
dence scale [29]. During the course of the intervention,
all participants will record any falls that take place and
submit monthly fall records to the investigators.
Safety of the exercise program The safety of the exer-
cise program will be assessed by recording the incidence
and severity of any adverse events and skeletal complica-
tions throughout the intervention. Skeletal complica-
tions include pain at known bone metastases sites and
pathological skeletal fractures [17]. Bone pain will be
monitored according to the Common Terminology
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Criteria of the National Cancer Institute: grade 1 mild,
not interfering with function; grade 2 moderate pain
interfering with function but not interfering with the
activities of daily life; and grade 3 severe pain, severely
interfering with the activities of daily living. In the pre-
sence of bone pain, patients will cease the exercise pro-
gram and undergo standard clinical evaluation,
including plain x-rays and other more specialised ima-
ging, as deemed appropriate.
Body composition Regional and whole body lean mass
(including appendicular skeletal muscle mass) and fat
mass will be derived from a whole body dual-energy X-
ray absorptiometry scan (Hologic Discovery A, Wal-
tham, MA). Measurement of trunk adiposity is an
important indicator of chronic disease risk, and will be
assessed from trunk fat mass obtained from the whole
body scan and the ratios of trunk fat to limb fat, and
trunk fat to total fat.
Muscle density and cross-sectional area Peripheral
Quantitative Computed Tomography (XCT3000, Stratec,
Pforzheim, Germany) will be used to measure muscle
density (an indicator of fat infiltration within the muscle
and hence muscle quality) and muscle cross-sectional
areas of the upper and lower limbs [30].
Health-related quality of life, bone pain and the late
life - function index Health-related quality of life out-
comes on general health, pain, vitality, social function-
ing, emotional role, and mental health will be measured
using the SF-36 [31]. The FACIT-Bone Pain question-
naire will be used to assess the nature, severity and
impact of bone pain [32]. The Late Life - Function
Index (LL-FI) will be used to assess patient-reported
physical functioning [33].
Anxiety and depression The Brief Symptom Inventory-
18 will provide a global measure of current psychologi-
cal distress with subscale scores for anxiety, depression,
and somatisation [34].
Cancer specific distress The Impact of Events Scale
(IES) and the Memorial Anxiety Scale for Prostate Can-
cer (MAX-PC) will be used to measure cancer specific
distress [35,36]. The IES has 15 items and contains two
subscales: Intrusion and Avoidance [36]. Intrusion can
also be used as a proxy measure for rumination about
cancer. The MAX-PC consists of 18 items and assesses
cancer specific distress across three domains: Prostate
Cancer Anxiety; Prostate Specific Antigen (PSA) Anxi-
ety; and Fear of Recurrence [35].
Fatigue Fatigue will be assessed using the Functional
Assessment of Chronic Illness Therapy-Fatigue (FACIT-
F) questionnaire. The FACIT-F is a 13-item scale com-
monly used to assess fatigue in cancer patients [37] as
well as cancer patients receiving exercise interventions
[38].
Sleep quality Items from the Pittsburgh Sleep Quality
Index (PSQI) will be used to measure sleep quality [39].
The PSQI is used to asses quality of sleep over a 1-
month interval, and has been shown to be reliable and
sensitive to change [40].
Physical activity motivation The Theory of Planned
Behaviour (TPB) is the most widely utilised behavioural
framework when examining physical activity motivation
in cancer survivors [41]. Therefore, physical activity
motivation will be assessed in accordance with the TPB.
TPB constructs (affective and instrumental attitude,
injunctive and descriptive norm, self-efficacy, perceived
behavioural control, intention, and planning) will be
assessed in accordance with established guidelines [41].
Physical activity level Self report physical activity level
will be assessed by the Godin Leisure-Time Question-
naire. ActiGraph activity monitors (triaxial acceler-
ometer) will be used to objectively assess physical
activity levels over a 7-day period [42]. A 6-item seden-
tary questionnaire will be used to assess the level of
sedentary behaviour.
Tolerance of the program Tolerance of the exercise
program will be evaluated by recording participants’ rat-
ings of perceived exertion on a Borg scale after every
exercise session. Additionally, a custom designed survey
examining exercise tolerance using a 7-point Likert
scale will be administered prior to the first exercise ses-
sion each week. The number of participants completing
the 3-month program as well as the number of sessions
attended will be recorded.
Other monitoring measures
Prostate specific antigen (PSA) PSA will be assessed at
baseline, 3 months (end of the intervention) and 6
months follow-up by an accredited National Association
of Testing Authorities laboratory (Pathwest Diagnostics,
Perth, Western Australia).
Exercise intervention
The modular multi-modal physical exercise intervention
program (M3EP) will comprise resistance, aerobic and
flexibility exercises undertaken 3 times per week in an
exercise clinic setting supervised by an exercise physiol-
ogist. Exercise training sessions will take approximately
60 min (this includes the warm-up and cool-down peri-
ods) and will be conducted in the Exercise Clinics at
Edith Cowan University in Perth, and at the University
of Newcastle’s Central Coast campus in Ourimbah. The
programme will include 6 exercises that target the
major trunk, upper and lower body muscle groups,
which we have used in a number of previous studies
[21-23,27,43-46] including men on ADT. There will be
a modular component for the resistance exercise pre-
scription based on location/extent of bone metastases
(Table 2). To ensure the progressive nature of the
Galvão et al. BMC Cancer 2011, 11:517
http://www.biomedcentral.com/1471-2407/11/517
Page 4 of 7
training program, subjects will be encouraged to work
past the specific repetition maximums (RMs) prescribed.
The resistance will be increased by 5-10% increment for
the next set/training session if subjects are able to per-
form more repetitions than the RMs specified during a
set. Moderate intensity and volume of resistance exer-
cise will range from 10 to 12-RM (e.g. the maximal
weight that can be lifted 10 to 12 times) using 3 sets per
exercise. This program differs considerably from those
commonly prescribed for survivors with localised pros-
tate cancer. Specifically, the M3EP is designed to mini-
mise compressive and shear loads on affected skeletal
sites to account for the reduced load bearing capabilities
of bone due to metastatic disease in specific regions.
Such loading is considerably below the forces exerted
on the skeleton during tasks of daily living such as des-
cending stairs or stepping down from a height and will
be similar to that of walking. All exercises will be per-
formed at a set cadence of 2 s for both eccentric and
concentric phases further minimizing peak forces trans-
mitted to the skeleton. Aerobic exercise component of
the M3EP will also be based on location/extent of bone
metastases with those with pelvis, axial skeleton (lum-
bar), proximal femur and all regions bone metastatic
disease undergoing non-weight bearing activities (Table
2). The aerobic component will include 20-30 min of
cardiovascular exercise using various modes such as
walking on a treadmill, cycling or rowing a stationary
ergometer, or exercising on a cross training machine
based on disease extent (Table 2). Target intensity will
be 60%-85% estimated maximum heart rate (220 - age)
with individual heart rate monitors (Polar Electro Oy,
Finland) provided for each participant. The flexibility
component of the M3EP will involve static stretching of
all the joint ranges of motion considered important for
function. Those with axial skeleton and all regions bone
metastases will be excluded from undertaking spine
flexion/extension/rotation (Table 2). The protocol will
involve 2-4 sets per muscle group at 30-60 s per set as
previously proposed [47]. All M3EP sessions will be
conducted in small groups of up to 8 participants under
direct supervision to ensure correct technique and mini-
mal risk of injury. Each session will commence with a
10-minute warm-up comprising low-level aerobic activ-
ities such as treadmill walking and stationary cycling as
determined by bone metastases site, as well as stretching
and conclude with a 5-minute cool-down period of
stretching activities. The M3EP will be designed to pro-
vide adequate stimulus to the cardiorespiratory, skeletal
and neuromuscular systems while maximizing compli-
ance and retention. All participants will be asked to
maintain customary physical activity and dietary pat-
terns over the intervention period (apart from the pro-
grammed exercise). Dietary intake will be assessed at
baseline, 3 and 6 months using 3-day record. During the
course of the study, participants will be required to
maintain an activity log and record their recreational
physical activities.
Statistical analysis
Data will be analysed using the SPSS statistical software
package and an intention-to-treat approach will be
applied. Analyses will include standard descriptive statis-
tics, Student’s t tests, correlation and regression, and
two-way (group × time) repeated measures ANOVA (or
ANCOVA as appropriate) to examine differences
between groups over time. All tests will be two-tailed
and an alpha level of 0.05 will be applied as the criterion
for statistical significance.
Discussion
Prostate cancer patients with bone metastases experi-
ence considerable morbidity resulting from skeletal
complications and often fatigue secondary to che-
motherapy [3,7]. Delaying or preventing skeletal compli-
cation and improving physical function for men with
bone metastases would provide clinically meaningful
benefits to patients. However, exercise programs must
be designed and executed with careful consideration of
the skeletal complications associated with bone meta-
static disease and cumulative toxicities from androgen
deprivation such as osteoporosis and increased risk of
fractures. Currently, such patients are unable to follow
existing exercise guidelines established for patients with
localised prostate cancer given the absence of exercise-
related data for this population. Consequently, the
results from this study will form the basis for the devel-
opment of a specific exercise prescription in this patient
group in order to alleviate disease burden, counteract
the adverse treatment related side-effects and enhance
quality of life. This project is unique as it will be the
Table 2 Modular multi-modal physical exercise program
(M3EP) for prostate cancer with bone metastases
Metastases site Exercise mode
Resistance Aerobic Flexibility
Upper Trunk Lower WB NWB Static
Pelvis √ √ √** √ √
Axial Skeleton (lumbar) √ √ √ √***
Axial Skeleton
(thoracic/ribs)
√* √ √ √ √***
Proximal Femur √ √ √** √ √
All regions √* √** √ √***
√ = Target exercise region; * = exclusion of shoulder flexion/extension/
abduction/adduction - inclusion of elbow flexion/extension; ** = exclusion of
hip extension/flexion - inclusion of knee extension/flexion; WB weight bearing
(e.g. walking); NWB non-weight bearing (e.g. cycling); *** = exclusion of spine/
flexion/extension/rotation.
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first study examining if a modular multi-modal targeted
exercise program incorporating resistance, aerobic and
flexibility exercise is safe and well tolerated by prostate
cancer patients with bone metastases. In terms of
advancement of prostate cancer care, we expect dissemi-
nation of the knowledge gained from this project to
reduce fracture risk, improve physical and functional
ability, quality of life and ultimately survival rates in this
population. Lastly, the proposed study will provide
strong, innovative information that has the potential to
directly influence current clinical recommendations for
other advanced cancer patients with bone metastases.
Although the intervention in this study will be highly
supervised and targeted to patient’s specific needs, given
the nature of the modular prescription approach, it has
the potential to be performed and implemented in dif-
ferent centres and at the community level thereby
reaching a significant number of patients.
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